BusinessCompanies

GlaxoSmithKline says no China bribery found

GlaxoSmithKline says that after a four-month investigation after receiving anonymous complaints it has found “no evidence of corruption or bribery in our China business.”

PUBLISHED : Thursday, 13 June, 2013, 3:15pm
UPDATED : Thursday, 13 June, 2013, 3:15pm
 

Drug manufacturer GlaxoSmithKline said on Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing.

The company said it conducted a four-month investigation after receiving complaints from an anonymous source. It said it found “no evidence of corruption or bribery in our China business.”

GlaxoSmithKline is headquartered in Britain but has a presence in the United States, which could make it liable to penalties under US anti-bribery laws.

The Wall Street Journal, citing company documents, reported the complaint said GlaxoSmithKline staff in China provided doctors with speaking fees, cash payments, lavish dinners and travel in return for prescribing its products.

“We have used significant resources to thoroughly investigate each and every claim from this single, anonymous source and have found no evidence of corruption or bribery in our China business,” said GlaxoSmithKline in a statement.

“GSK wants to reiterate to its patients, staff and partners in China that these allegations are false.”

Share

 

Send to a friend

To forward this article using your default email client (e.g. Outlook), click here.

Enter multiple addresses separated by commas(,)

For unlimited access to:

SCMP.com SCMP Tablet Edition SCMP Mobile Edition 10-year news archive